Phase 1Completed
A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas
A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas
- Sponsor
- PCI Biotech AS (Industry)
- Enrollment
- 24 enrolled
- Conditions
- Cholangiocarcinoma
- Interventions
- Amphinex, Gemcitabine and Cisplatin
- Ages
- adults, older adults
- Registry
- NCT01900158, EUCTR2012-002888-10
Full record on ClinicalTrials.gov
From the registry
This is a Phase I Dose Escalation Study in which the safety, tolerability and efficacy of Amphinex®--induced Photochemical Internalisation (PCI) of Gemcitabine followed by Gemcitabine/Cisplatin Chemotherapy will be assessed in patients with advanced inoperable cholangiocarcinomas.
Primary outcomes
- Dose-limiting toxicities (DLT) and the safety profile
- Schedule-limiting toxicities (SLTs) and the safety profile
History
Last registry update
Primary completion
Registered
Started